Protagenic Therapeutics (PTIX) — Cash Flow Quality Index
Protagenic Therapeutics (PTIX) has a Cash Flow Quality Index of -0.07x as of December 2025. Operating cash flow of $-410.42K is below net income of $5.83 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Protagenic Therapeutics debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Protagenic Therapeutics Cash Flow Quality Index (1998–2006)
Historical Cash Flow Quality Index for Protagenic Therapeutics across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see PTIX cash flow conversion.
Annual Cash Flow Quality Index for Protagenic Therapeutics (1998–2006)
Year-by-year earnings quality comparison for Protagenic Therapeutics.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2006 | 1.38x | $931.00K | $677.00K | ▼ -86.8% |
| 2001 | 10.44x | $1.50 Million | $144.00K | ▲ +238.2% |
| 2000 | 3.09x | $3.51 Million | $1.14 Million | ▲ +561.1% |
| 1998 | -0.67x | $-434.00K | $648.00K | — |